Zynex Inc. (OTCMKTS:ZYXI) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Thursday.

Zynex (OTCMKTS ZYXI) remained flat at $0.42 during trading on Thursday. 7,833 shares of the company traded hands. The stock has a market capitalization of $13.46 million, a PE ratio of 19.09 and a beta of 0.11. Zynex has a 12-month low of $0.10 and a 12-month high of $0.42. The stock has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.33.

Zynex (OTCMKTS:ZYXI) last issued its quarterly earnings results on Monday, May 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $3.44 million for the quarter. Analysts forecast that Zynex will post ($0.24) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/08/zynex-inc-zyxi-rating-increased-to-hold-at-valuengine.html.

About Zynex

Zynex, Inc operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Zynex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex Inc. and related companies with MarketBeat.com's FREE daily email newsletter.